Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: Outpatient management for adults

American Journal of Health-System Pharmacy

Volumn 56, Issue 15, 1999, Pages 1505-1514

  Sachdev, Gloria P ^a   Ohlrogge, Kristen D ^b   Johnson, Carrie L ^c  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Good Samaritan Hospital Dayton   (United States)

Author keywords

American College of Chest Physicians; Anticoagulants; Dosage; Dosage schedules; Hemorrhage; International Normalized Ratio; Patients; Protocols; Surgery; Thrombophlebitis; Thrombosis; Toxicity; Warfari n

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY BYPASS; BLEEDING; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; INTERNATIONAL STANDARD UNIT; OUTPATIENT CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; STROKE; THROMBOEMBOLISM; THROMBOPHLEBITIS; VALVULAR HEART DISEASE;

EID: 0033180135     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.15.1505     Document Type: Review

References (62)

1. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 1998; 114(suppl):439S-769S.
2. Oral anticoagulation therapy. American College of Chest Physicians Consensus Conference Panel Recommendations. VHA satellite broadcast. 1998 Oct 29.
3. Harrison L, Johnston M, Massicotte MP et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 126:133-6.
4. Hull R, Hirsh J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982; 307:1676-81.
5. Turpie AGG, Gunstensen J, Hirsh J et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988; 1:1242-5.
6. Saour JN, Sieck JO, Mamo LAR et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990; 322:428-32.
7. Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991; 101:427-31.
8. 1. Ann Intern Med. 1997; 125:959-62.
9. 1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis. 1993; 4:739-41.
10. Crowther MA, Donovan D, Harrison L et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998; 79:1116-8.
11. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med. 1998; 158:1610-6.
12. Feinberg WM, Blackshear JL, Laupacis A et al. The prevalence of atrial fibrillation: analysis and implications. Arch Intern Med. 1995; 155:469-73.
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991; 22:983-8.
14. Lake FR, McCall MG, Cullen KJ et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med. 1989; 19:321-6.
15. Phillips SJ, Whisnant JP, O'Fallon WM et al. Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc. 1990; 65:344-59.
16. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74:238-41.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-57.
18. EAFT Study Group. European Atrial Fibrillation Trial: secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and a recent transient ischaemic attack or minor ischaemic stroke. Lancet. 1993; 342:1255-62.
19. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation III randomized clinical trial. Lancet. 1996; 348:633-8.
20. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA. 1998; 279:1273-7.
21. Connolly SJ, Laupacis A, Gent M et al., for the CAFA Study Co-investigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991; 18:349-55.
22. Peterson P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989; 1:175-8.
23. Stroke Prevention In Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991; 84:527-39.
24. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323:1505-11.
25. Ezekowitz MD, Bridges SL, James KE et al., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-12.
26. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335:540-6.
27. Cates JE, Christie RV. Subacute bacterial endocarditis: a review of 442 patients treated in 14 centers appointed by the penicillin trials committee of the MRC. Q J Med. 1951; 20:93.
28. Brunson JG. Coronary embolism in bacterial endocarditis. Am J Pathol. 1953; 26:689.
29. Lerner PI, Weinstein L. Infective endocarditis in the antibiotic era. N Engl J Med. 1966; 274:388-93.
30. Pruitt AA, Rubin RH, Karchmer AW et al. Neurologic complications of bacterial endocarditis. Medicine. 1978; 57:329-43.
31. Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve endocarditis. South Med J. 1983; 76:1372-5.
32. Garvey CJ, Neu HC. Infective endocarditis: an evolving disease. Medicine. 1979; 57:105-26.
33. Block PC, DeSanctis RW, Weinberg AN. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 1970; 60:540-8.
34. Wilson WR, Geraci JE, Danielson GK et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation. 1978; 57:1004-7.
35. Manson JE, Stampfer J, Colditz GA et al. A prospective study of aspirin use and primary prevention in cardiovascular disease in women. JAMA. 1991; 266:521-7.
36. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998; 351:233-41.
37. Yli-Mayry S, Huikuri HV, Korhonen UR et al. Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion. Eur Heart J. 1992; 13:1259-64.
38. Van der Meer J, Brutel de la Riviere A, Van Gilst WH et al. Effects of low dose aspirin (50mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. J Am Coll Cardiol. 1994; 24:1181-8.
39. Boneu B, Caranobe C, Cadroy Y et al. Pharmacokinetic studies of standard UFH and low molecular weight heparin in the rabbit. Semin Thromb Hemost. 1988; 14:18-27.
40. Caranobe C, Barret A, Gabaig AM et al. Disappearance of circulating anti-Xa activity after intravenous injection of unfractionated heparin and of low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res. 1985; 40:129-33.
41. Palm M, Mattsson CH. Pharmacokinetics of heparin and low molecular weight fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 1987; 58:932-5.
42. Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery. Clin Orthop. 1989; 242:212-31.
43. Sikarski JM, Hampson WG, Staddon GE. The natural history and etiology of deep venous thrombosis after total hip replacement. J Bone Joint Surg Br. 1981; 63:171-7.
44. Levine M, Jent M, Hirsh J et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334:677-81.
45. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared to subcutaneous low-molecular weight heparin administered at home. N Engl J Med. 1996; 334:682-7.
46. The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 337:657-62.
47. Simmonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997; 337:663-9.
48. A Collaborative European Multicentre Study. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost. 1991; 65:251-6.
49. Prandoni P, Lensing AWA, Buller HR et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal venous thrombosis. Lancet. 1992; 339:441-5.
50. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 1992; 326:975-82.
51. Lindmarker P, Holmstrom M, Granquist S et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous heparin in the treatment of deep venous thrombosis. Thromb Haemost. 1994; 72:186-90.
52. Luomanmaki K, Granqvist S, Hallert C et al. A multicentre comparison of once-daily subcutaneous dalteparin and continuous intravenous heparin in the treatment of deep venous thrombosis. J Intern Med. 1996; 240:85-92.
53. Sachs BP, Brown DA, Driscoll SG et al. Maternal mortality in Massachusetts: trends and prevention. N Engl J Med. 1987; 316:607-72.
54. Report on confidential inquiries Into maternal deaths for England and Wales 1979-1981. London, England: Her Majesty's Stationery Office. 1986.
55. Bonnar J. Venous thromboembolism and pregnancy. Clin Obstet Gynecol. 1981; 8:455-73.
56. De Swiet M, Floyd E, Letsky E. Low risk of recurrent thromboembolism in pregnancy. Br J Hosp Med. 1987; 38:264. Letter.
57. Howell R, Fidler J, Letsky E et al. The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynecol. 1983; 90:1124-8.
58. Badaracco MA, Vessey M. Recurrent venous thromboembolic disease and use of oral contraceptives. Br Med J. 1974; 1:215-7.
59. Tengborn L. Recurrent thromboembolism in pregnancy and pueriperium: is there a need for thromboprophylaxis? Am J Obstet Gynecol. 1989; 160:90-4.
60. Flessa HC, Klapstrom AB, Glueck MJ et al. Placental transport of heparin. Am J Obstet Gynecol. 1965; 93:570-3.
61. Hall JAG, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation in pregnancy. Am J Med. 1980; 68:122-40.
62. Becker MH, Genieser NB, Finegold M et al. Chondrodysplasia punctata: is maternal warfarin a factor? Am J Dis Child. 1975; 129:356-9.